The FDA's Center for Research on Complex Generics (CRCG) is hosting a two-day hybrid workshop in September 2026 focused on navigating the regulatory pathway for generic GLP-1 drugs. This initiative is part of a broader effort to address the scientific challenges associated with approving complex generic medicines, which often lack market competition due to difficult bioequivalence requirements.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.